[go: up one dir, main page]

RU2002105375A - APPLICATION OF GABAB RECEPTOR AGONISTS AND THEIR PHARMACEUTICALLY ACCEPTABLE DERIVATIVES FOR SUPPORTING THERAPY OF NICOTINE-DEPENDENT PATIENTS - Google Patents

APPLICATION OF GABAB RECEPTOR AGONISTS AND THEIR PHARMACEUTICALLY ACCEPTABLE DERIVATIVES FOR SUPPORTING THERAPY OF NICOTINE-DEPENDENT PATIENTS

Info

Publication number
RU2002105375A
RU2002105375A RU2002105375/14A RU2002105375A RU2002105375A RU 2002105375 A RU2002105375 A RU 2002105375A RU 2002105375/14 A RU2002105375/14 A RU 2002105375/14A RU 2002105375 A RU2002105375 A RU 2002105375A RU 2002105375 A RU2002105375 A RU 2002105375A
Authority
RU
Russia
Prior art keywords
use according
gaba
transdermal
nicotine
baclofen
Prior art date
Application number
RU2002105375/14A
Other languages
Russian (ru)
Other versions
RU2262352C2 (en
Inventor
Джиан Луиджи ДЖЕССА
Джианкарло КОЛОМБО
Лука ПАНИ
Вальтер ФРАТТА
Original Assignee
Л.Мольтени Энд К.Дей Фрателли Алитти Сочиета' Ди Эсерчицио С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT1999MI001715A external-priority patent/IT1313585B1/en
Application filed by Л.Мольтени Энд К.Дей Фрателли Алитти Сочиета' Ди Эсерчицио С.П.А. filed Critical Л.Мольтени Энд К.Дей Фрателли Алитти Сочиета' Ди Эсерчицио С.П.А.
Publication of RU2002105375A publication Critical patent/RU2002105375A/en
Application granted granted Critical
Publication of RU2262352C2 publication Critical patent/RU2262352C2/en

Links

Claims (9)

1. Применение агонистов GABAB рецепторов, или их фармацевтически используемых производных, для получения фармацевтических композиций, предназначенных для уменьшения тяги к курению у никотин-зависимых пациентов при лечении никотиновой зависимости.1. The use of GABA B receptor agonists, or their pharmaceutically used derivatives, for the manufacture of pharmaceutical compositions intended to reduce smoking cravings in nicotine-dependent patients in the treatment of nicotine addiction. 2. Применение по п.1, отличающееся тем, что в качестве агонистов GABAB рецепторов используют β-(4-хлорфенил)GABA (Baclofen), 3-аминопропил(метил)фосфиновую кислоту, 3-аминопропилфосфиновую кислоту, γ-амино-β-4-(4-хлорфенил)нитропропан или их фармацевтически применимые производные, выбранные из группы, состоящей из их солей, сложных эфиров, простых эфиров, комплексов и их соответствующих изомеров.2. The use according to claim 1, characterized in that β- (4-chlorophenyl) GABA (Baclofen), 3-aminopropyl (methyl) phosphinic acid, 3-aminopropylphosphinic acid, γ-amino-β are used as agonists of GABA B receptors -4- (4-chlorophenyl) nitropropane or their pharmaceutically applicable derivatives selected from the group consisting of their salts, esters, ethers, complexes and their corresponding isomers. 3. Применение по п.2, отличающееся тем, что агонист GABAB рецепторов представляет собой Baclofen.3. The use according to claim 2, characterized in that the GABA B receptor agonist is Baclofen. 4. Применение по п.3, отличающееся тем, что агонист GABAB рецепторов представляет собой изомер R(-) Baclofen в виде свободного основания или его фармацевтически применимые производные, выбранные из группы, состоящей из их солей, сложных эфиров, простых эфиров и комплексов.4. The use according to claim 3, characterized in that the GABA B receptor agonist is an isomer of R (-) Baclofen in the form of a free base or its pharmaceutically applicable derivatives selected from the group consisting of their salts, esters, ethers and complexes . 5. Применение по п.1, отличающееся тем, что фармацевтическая композиция имеет форму, подходящую для перорального, парентерального, трансдермального введения или введения типа депо.5. The use according to claim 1, characterized in that the pharmaceutical composition is in a form suitable for oral, parenteral, transdermal administration or administration of a depot type. 6. Применение по п.5, отличающееся тем, что в качестве подходящих форм используют капсулы, таблетки, трансдермальные повязки, сублингвальные гели, внутримышечные препараты типа депо.6. The use according to claim 5, characterized in that capsules, tablets, transdermal dressings, sublingual gels, intramuscular preparations of the depot type are used as suitable forms. 7. Применение по п.6, отличающееся тем, что таблетки представляют собой таблетки пролонгированного действия и их получают с использованием замкнутых или матричных систем.7. The use according to claim 6, characterized in that the tablets are sustained release tablets and are prepared using closed or matrix systems. 8. Применение по п.5, отличающееся тем, что трансдермальные композиции представляют собой системы трансдермальной доставки лекарственного средства и трансдермальные терапевтические системы.8. The use according to claim 5, characterized in that the transdermal compositions are transdermal drug delivery systems and transdermal therapeutic systems. 9. Применение по п.8, отличающееся тем, что указанные средства представляют собой липкие приспособления, резервуарные приспособления, монолитные приспособления.9. The use of claim 8, characterized in that the said means are sticky devices, reservoir devices, monolithic devices.
RU2002105375/15A 1999-07-30 2000-06-30 Applying agonists of gamma-aminobutyric acid receptors of b-type and their pharmaceutically acceptable derivatives in treatment of nicotine dependence RU2262352C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999MI001715A IT1313585B1 (en) 1999-07-30 1999-07-30 USE OF GABAB RECEPTOR AGONISTS FOR THE MAINTENANCE THERAPY OF NICOTINE ABSTINENCE IN NICOTINO-EMPLOYEES.
ITM199A001715 1999-07-30

Publications (2)

Publication Number Publication Date
RU2002105375A true RU2002105375A (en) 2003-11-10
RU2262352C2 RU2262352C2 (en) 2005-10-20

Family

ID=11383467

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002105375/15A RU2262352C2 (en) 1999-07-30 2000-06-30 Applying agonists of gamma-aminobutyric acid receptors of b-type and their pharmaceutically acceptable derivatives in treatment of nicotine dependence

Country Status (16)

Country Link
EP (1) EP1202727B1 (en)
CN (1) CN1176650C (en)
AT (1) ATE285763T1 (en)
AU (1) AU6153400A (en)
CA (1) CA2379752C (en)
DE (1) DE60017147T2 (en)
DK (1) DK1202727T3 (en)
ES (1) ES2235913T3 (en)
HK (1) HK1046849B (en)
IL (2) IL147876A0 (en)
IT (1) IT1313585B1 (en)
PL (1) PL196334B1 (en)
PT (1) PT1202727E (en)
RU (1) RU2262352C2 (en)
SI (1) SI1202727T1 (en)
WO (1) WO2001008675A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
WO2005019163A2 (en) * 2003-08-20 2005-03-03 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
WO2006050471A2 (en) 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
US7494985B2 (en) 2004-11-03 2009-02-24 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
US7585996B2 (en) 2006-09-15 2009-09-08 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
JP4498407B2 (en) 2006-12-22 2010-07-07 キヤノン株式会社 Process cartridge, electrophotographic image forming apparatus, and electrophotographic photosensitive drum unit
JP5291123B2 (en) 2008-01-25 2013-09-18 ゼノポート，インコーポレイティド Crystal form of (3S) -aminomethyl-5-hexanoic acid prodrug and use thereof
US7872046B2 (en) 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
US7989641B2 (en) 2008-08-07 2011-08-02 Xenoport, Inc. Methods of synthesizing N-hydroxysuccinimidyl carbonates
WO2010017504A1 (en) 2008-08-07 2010-02-11 Xenoport, Inc. Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
CA2753057C (en) 2009-03-03 2018-09-11 Xenoport, Inc. Sustained release oral dosage forms of an r-baclofen prodrug
US8344028B2 (en) 2009-04-17 2013-01-01 Xenoport, Inc. Gamma-amino-butyric acid derivatives as GABAB receptor ligands
WO2011081558A1 (en) * 2009-08-21 2011-07-07 Komissarov Jury Vladimirovich Smoking device for giving up tobacco smoking
WO2013023155A1 (en) 2011-08-11 2013-02-14 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use
WO2019195813A1 (en) * 2018-04-06 2019-10-10 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of substance use disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US5073539A (en) * 1990-01-22 1991-12-17 Ciba-Geigy Corporation Transdermal administration of zwitterionic drugs
US5760049A (en) * 1997-02-21 1998-06-02 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
US6541520B1 (en) * 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
RU2132203C1 (en) * 1998-09-03 1999-06-27 Шакирзянов Галимзян Закирович Method of tobacco dependency treatment and antitobacco combination preparation

Similar Documents

Publication Publication Date Title
RU2002105375A (en) APPLICATION OF GABAB RECEPTOR AGONISTS AND THEIR PHARMACEUTICALLY ACCEPTABLE DERIVATIVES FOR SUPPORTING THERAPY OF NICOTINE-DEPENDENT PATIENTS
KR102398194B1 (en) Novel compositions and methods
RU2404750C2 (en) Composition containing base or coat for moderated release and antagonist of nmda receptor, method for introduction of such nmda antagonist to individual
ES2227814T3 (en) DOSAGE FORMS THAT INCLUDE SEPARATE PORTIONS OF ENANTIOMEROS R AND S.
JP2005512995A5 (en)
JP2005515966A5 (en)
AU2018420535B2 (en) Edaravone pharmaceutical composition
KR20060077812A (en) Sustained release combination preparations for oral administration of a diabetes treatment and preparation method thereof
JP2004534057A5 (en)
JP2007506766A5 (en)
US20210308040A1 (en) Ketamine oral transmucosal delivery system
RU2003116058A (en) COMPOSITIONS OF A HYDROCODON WITH CONTROLLED RELEASE
NZ231923A (en) Adhesive tablet comprising baclofen in a hydrophilic core with a hydrophobic coating
WO1999002158A1 (en) Stable medicinal compositions containing 4,5-epoxymorphinane derivatives
WO2003004032A1 (en) Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
EP1275381A4 (en) Time-release coated solid compositions for oral administration
KR102479497B1 (en) Sustained release pharmaceutical formulation of varenicline and preparation method thereof
CN113597303B (en) Transmucosal therapeutic system containing agomelatine
JP2002534477A5 (en)
KR20050009983A (en) Sustained release formulation of tramadol
KR20060039867A (en) Compositions and Methods for Treatment of HIV
JP2001508769A (en) Pharmaceutical composition comprising alendronate and an agent for promoting gastric emptying
WO2016137266A2 (en) Pharmaceutical composition containing eperisone and pelubiprofen
KR20060130006A (en) Oral sustained release tablets
JPWO2020247603A5 (en)